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Abstract
Uterine carcinosarcoma (UCS) has been proposed as a model for epithelial–mesenchymal transition (EMT), a process charac-
terized by a functional change facilitatingmigration andmetastasis in many types of cancer. L1CAM is an adhesionmolecule that
has been involved in EMT as a marker for mesenchymal phenotype. We examined expression of L1CAM in UCS in a cohort of
90 cases from four different centers. Slides were immunohistochemically stained for L1CAM and scored in four categories (0%,
< 10%, 10–50%, and > 50%). A score of more than 10% was considered positive for L1CAM. The median age at presentation
was 68.6 years, and half of the patients (53.3%) presented with FIGO stage 1 disease. Membranous L1CAM expression was
positive in the epithelial component in 65.4% of cases. Remarkably, expression was negative in the mesenchymal component. In
cases where both components were intermingled, expression limited to the epithelial component was confirmed by a double stain
for L1CAM and keratin. Expression of L1CAM did not relate to overall or disease-free survival. Our findings suggest L1CAM is
either not a marker for the mesenchymal phenotype in EMT, or UCS is not a good model for EMT.
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Introduction
Uterine carcinosarcoma (UCS) is a rare subtype of endo-
metrial cancer (EC) with a poor prognosis. Approximately
60% of cases present with advanced disease, and recur-
rence occurs in approximately 50% of patients [1–4].
Accordingly, 5-year survival ranges from 33 to 39%.
Histology is peculiar because it contains both an epithelial
as well as a mesenchymal component [1, 5]. Various
models have been proposed to explain this feature ranging
from collision of two separate and original components to
conversion of a common monoclonal neoplasm of epithe-
lial (carcinomatous) origin [5–8]. Currently, most studies
support the theory of conversion of an endometrial carci-
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Because UCS contains both an epithelial and mesenchy-
mal component, UCS has been suggested as a model for
epithelial–mesenchymal transition (EMT) [5, 9–14]. EMT
is a process that is characterized by a functional change in
tumor cells that facilitates migration and metastasis [11,
15]. By loss of cell polarity and cell–cell junctions, and
by reorganization of their cytoskeleton, tumor cells acquire
the ability to migrate. This transformation is thought to be
essential to metastasis in gynecologic cancers as well as
other tumors [13, 16]. In a study on 76 cases of UCS,
Castilla et al. found a different expression of epithelial
and mesenchymal markers between the two components.
Expression of E-cadherin for example was limited to the
epithelial component.
A possible marker for a mesenchymal phenotype is L1
cell adhesion molecule (L1CAM), a transmembrane adhe-
sion molecule important for embryonic development [17].
The extracellular domain interacts with other binding mol-
ecules and integrins expressed on either the same or other
cells. The cytoplasmic tail mainly interacts with cytoskel-
etal proteins. Several studies support involvement of
L1CAM in EMT [18–21]. Exposure of both endometrial
cancer (EC) and breast cancer cell lines to transforming
growth factor B1 (TGF-B1), a known inducer of EMT,
results in increased expression of L1CAM [19, 21].
Huszar et al. found that increased expression of L1CAM
relates to reduced membranous expression of E-cadherin.
L1CAM could be a marker for a mesenchymal phenotype
of EMT in UCS.
Expression of L1CAM previously described as immu-
nohistochemical staining of more than 10% is absent in
normal endometrium [22]. In addition, expression of
L1CAM is related to metastasis and poor prognosis in
many cancers, including EC [17, 22–28]. In early-stage
EC with endometrioid histology, expression of L1CAM
is related to unfavorable pathological findings, distant
recurrence and poor survival [22, 23]. Correspondingly,
in high grade EC and non-endometrioid EC (NEEC),
L1CAM expression is related to unfavorable pathological
findings such as advanced stage and lymphovascular
space invasion (LVSI) as well as distant recurrence but
not survival [26–28].
We hypothesize that L1CAM could be involved in EMT
in UCS as a marker for the mesenchymal phenotype and
may relate to metastasis. Therefore, we aimed to evaluate
L1CAM expression in a large cohort of 90 UCS patients
assembled in 4 oncologic centers participating in the
European Network for Individualized Treatment of
Endometrial Cancer (ENITEC) collaboration. Expression
was evaluated separately in the epithelial and the mesen-




Four-micrometer formalin-fixed slides were assembled from
four separate centers (Haukeland University hospital Bergen,
Norway; University hospital Lleida, Spain; Leiden University
Medical Center, The Netherlands; and University Medical
Center Groningen, the Netherlands). Sufficient material from
88 primary tumors and 10 metastases was available. With an
overlap of 8 cases, this added up to a total of 90 cases with
UCS diagnosed between 1980 and 2012 to be included in this
study. Data concerning age at diagnosis, International
Federation of Gynecology and Obstetrics (FIGO) stage as
well as patient and tumor characteristics concerning age at
diagnosis, histology of both components (homologue or
heterologue for the epithelial component), differentiation
grade, LVSI, were delivered by each participating center. All
material was revised at the University Medical Center
Groningen by HH and MV blinded from findings at the pri-
mary center. For some cases, clinicopathological information
was missing and could not be retrieved from the slides, for
example, when information on lymphovascular space in-
volvement was missing. Follow-up data was provided by each
center in an anonymized dataset and completed until October
2014. Datasets were combined into a final password-protected
database. Patient identity was protected by study-specific pa-
tient numbers. Informed consent was obtained according to
local protocol in each participating center.
Histology
Slides, 4-μm formalin-fixed paraffin-embedded sections were
immunohistochemically stained as described by Bosse et al.
[23]. BBriefly, formalin fixed paraffin-embedded (FFPE) tis-
sue blocks were cut into 4 μm slides and mounted on Starfrost
slides. Antigen retrieval was achieved by microwave oven
procedure in 10 mmol/L citrate buffer, pH 6. Sections were
incubated overnight with primary monoclonal antibodies
against L1CAM (CD171, clone 14.10, SIG-3911, Convance
Inc., lot number D13KF03087, Biolegend, San Diego, USA)
in a 1:500 dilution. Sections were incubated and stained for
30 min using a secondary antibody (Poly-HRP-GAM/R/R;
DPV0110HRP; ImmunoLogic, Duiven, The Netherlands). The
slides were counterstained with Mayer’s Haematoxylin,
dehydrated and mounted. Omission of the primary antibody
was used as a negative control and a highly L1CAM-
expressing serous ovarian cancer as an external positive control.^
In eight cases, it was difficult to differentiate between
L1CAM expression by the epithelial or mesenchymal compo-
nents as both components were intermingled. Therefore, these
selected cases were double stained for both L1CAM and
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cytokeratin-8 as expression of cytokeratin is limited to the
epithelial component. Tissue sections were dewaxed in xylene
and hydrated in a graded series of alcohol to tap water.
Antigen retrieval was performed in 10 mM EDTA pH 8.0 in
a microwave at 400 W for 15 min. Endogenous peroxidase
was blocked by incubating sections for 30 min in 1% H2O2.
Primary antibody against L1CAM (anti-CD171, Biolegend,
Sig-3911-1000, San Diego, USA) was applied in a 1:500 di-
lution and left to incubate overnight at 4 °C. Subsequently,
tissue sections were incubated with secondary antibody
(RAM-HRP; Dako, Glostrop, Denmark) and tertiary antibody
(GAR-HRP; Dako, Glostrop, Denmark), both diluted at
1:100, for 30 min each at room temperature. L1CAM staining
was visualized with 3,3′-diaminobenzidine. After washing the
sections in demineralized water, they were incubated with the
antibody against cytokeratin-8 (CAM 5.2, BD Biosciences,
#345779) diluted 1:5 for 1 h at room temperature. Sections
were then incubated with secondary antibody (RAMbio;
Dako) and tertiary antibody (streptavidin-AP; Dako), both
diluted 1:300, for 30 min each at room temperature.
Cytokeratin staining was visualized using Fast Blue BB/
Napthhol-AS-MX-phosphate (Sigma, F3378) for 30 min at
room temperature. Sections were rinsed with demineralized
water and mounted with Kaiser’s glycerol gelatine (109242;
Merck). Omission of the primary antibody was used as a neg-
ative control and tonsil tissue as a positive control.
Evaluation of immunohistochemistry
Evaluation of immunohistochemistry was performed by two
independent investigators (MV and AP), blinded for clinical
outcome data. Expression of L1CAM in either component
was scored as the percentage of positive membranous staining
and categorized into four groups: 0%, 0–10%, 10–50%, or >
50% as described by Meier et al. [29]. In conformity with
previous publications, tumors with more than 10% expression
of L1CAM were considered positive [23, 29]. There was no
disagreement in evaluation of the mesenchymal component.
There was disagreement in evaluation of 21 cases of the car-
cinomatous component mainly on a score of either 3 or 4.
Disagreement was resolved by consensus. Location of
L1CAM staining was scored as expression at the tumor center,
tumor margin, or diffusely over the tumor.
Statistical analysis
All statistical analyses were done by using SPSS (version 23,
IBM Statistics, Chicago USA). For analysis, age was dichot-
omized into 65 and below versus above 65 years as this is an
important cutoff in treatment of endometrial cancer.
Recurrence was classified as local, pelvic, or distant.
Disease-free survival (DFS) was defined as time until any
recurrence or death of disease and disease-specific survival
(DSS) as time until death of disease. Associations between
patient and tumor characteristics were compared using logistic
regression analyses. For survival analysis, a relation between
L1CAM expression and DFS, DSS, or distant recurrence was
examined using Cox regression analyses. Patients without ev-
idence of disease were censored at last date of follow-up.
Results
Population
Tissue from the primary tumor was available in 88 cases. In 10
cases, metastatic tissue was available. With an overlap of 8
cases (primary as well as metastatic tissue), this added up to a
Table 1 Patient and tumor characteristics in 90 cases of uterine
carcinosarcoma (UCS). FIGO = International Federation of Gynecology
and Obstetrics
Number % or IQR
Median age (years) 68.6 62.0–75.5
FIGO stage (2009)
- I and II 50 55.36
- III and IV 40 44.4
Myometrial invasion
- Less than 50% 43 53.1
- More than 50% 38 46.9
- Unknown 9
Lymph node status
- Negative 36 78.3
- Positive 10 21.7
- Unknown 44
Lymphovascular space invasion (LVSI)
- No 24 36.4
- Yes 42 63.6
- Missing 24
Differentiation grade carcinoma component
- Grade 2 6 8.3
- Grade 3 63 87.5
- Undifferentiated 3 4.2
- Unknown 18
Histologic type carcinoma component
- Endometrioid 27 39.1
- Non-endometrioid 42 60.9
- Unknown 21
Histologic type sarcoma component
- Homologue 39 53.4
- Heterologue 34 46.6
- Unknown 17
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total of 90 cases to be evaluated. Not all tissue contained
both components. The epithelial component was available
in 81 cases and the mesenchymal component in 83 cases.
Patient and tumor characteristics are shown in Table 1. The
median age at diagnosis was 68.6 years (IQR 62.0–75.5).
A small majority of cases presented with FIGO stage 1
disease (53.3%), most other cases presented with stage 3a
or 3c disease (14.4 vs 12.2%). LVSI was observed in
53.8%, and non-endometrioid histology of the epithelial
component was 56.5%.
Immunohistochemistry
Figure 1 shows examples of L1CAM expression in both com-
ponents. Expression was not limited to either the tumor center
or margin.
Table 2 shows the results of L1CAM staining. The epithe-
lial component was L1CAM positive in a majority of cases
(65.4%). Remarkably, the mesenchymal component was de-
termined as negative (< 10%) for L1cam in all cases. In
86.7%, no expression was found. In 13.3%, L1CAM
Fig. 1 L1CCAM staining in
carcinosarcoma. a L1CAM
expression scored as 0%. b
L1CAM expression scored as less
than 10%. c L1CAM expression
scored as 10–50%,. d L1CAM
expression scored as more than
50%. All figures are presented at
× 10 magnification
Table 2 Expression of L1CAM in both components in 88 primary UCS tumors and 7 metastatic tumors
Epithelial component,
primary tumor, n (%)
Mesenchymal component,





0% expression 16 (20.2) 72 (86.7) 1 (12.5) 4 (80)
< 10% expression 11 (15.2) 11 (13.3) 3 (37.5) 1 (20)
10–50% expression 22 (27.8) 4 (50.0)
> 50% expression 30 (38.0)
Component not available 9 5 2 5
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expression was scored less than 10%. In some of these cases,
both components were intermingled and therefore difficult to
distinguish. To differentiate between L1CAM expression by
either component, a double stain for L1CAM and keratin was
performed in eight cases. In all eight cases, L1CAM expres-
sion was limited to cells expressing keratin. Figure 2 shows
examples of double staining for L1CAM.
Patient and tumor characteristics in relation to L1CAM
expression
Table 3 shows patient and tumor characteristics stratified for
L1CAM expression. Logistic regression showed no relation
between patient or tumor characteristics and L1CAM expres-
sion. L1CAM expression survival in the overall cohort was
poor with a median DFS of 2.83 years (95%CI 0.80–4.87) and
DSS of 3.30 (1.10–5.50). Known prognostic variables related
to DFS in univariate Cox regression analysis: FIGO stage (HR
1.67 95%CI 1.30–2.14), myometrial invasion (HR 1.80
95%CI 0.96–3.34), and differentiation grade (HR 3.81
95%CI 1.13–12.80). LVSI was not a significant predictor for
DFS. Findings were similar for DSS. Expression of L1CAM
did not relate to either DFS (HR 1.48 95%CI 0.74–3.00) or
DSS (HR 1.48 95%CI 0.74–3.00). There was also no relation
between L1CAM expression and distant recurrence (HR1.02
95%CI 0.45–2.30).
Discussion
L1CAM is frequently expressed in UCS, but expression in
UCS is limited to the epithelial component. Expression does
not relate to patient characteristics, recurrence, or survival.
Expression of L1CAM in UCS is in accordance with other
studies on L1CAM expression in aggressive histologic sub-
types of EC such as non-endometrioid EC. These studies de-
scribe an L1CAM expression of more than 55% and no rela-
tion with survival [22, 23, 27]. We also find a high percentage
Fig. 2 Examples of double stain for L1CAM (brown) and keratin (blue).
a HE stain of case 8. This case was originally scores as L1CAM expres-
sion > 50% in the epithelial component and 0% in the mesenchymal
component. b Double stain for L1CAM and keratin in case 8. c HE stain
for case 9. This case was originally scores as L1CAM expression > 50%
in the epithelial component and 0% in the mesenchymal component. d
Double stain for L1CAM and keratin in case 9. e HE stain for case 14.
This case was originally scored as L1CAM expression > 50% in the
epithelial component and < 10% in the mesenchymal component. f
Double stain for L1CAM and keratin in case 14. All figures are presented
at × 10 magnification
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of L1Cam positive tumors and no relation between L1CAM
expression and survival. A strong relation between expression
and survival is therefore unlikely. An explanation for the ab-
sence of a relation could be the already poor survival in co-
horts of NEEC and the high expression of L1CAM in NEEC
as compared to EEC as suggested by van der Putten et al. [27].
Remarkably, L1CAM expression is not expressed in the mes-
enchymal component. Our working hypothesis was that
L1CAM expression could act as a marker for a mesenchymal
component in UCS. Several other studies describe increased
expression of L1CAM after induction of EMT. In endometrial
cancer cell lines, TGF-B1 induces expression of L1CAM and
EMT [19, 21]. Exposure to TGF-B1 results in increased ex-
pression of L1CAM through upregulation of the EMT tran-
scription factor Slug. In turn, expression of L1Cam relates to
cell migration and invasion [21]. TGF-B1-induced L1CAM
expression is related to decreased expression of E-cadherin,
and E-cadherin expression is limited to the epithelial compo-
nent in UCS [10, 19]. Considering our findings, L1CAM is
either not a marker for the mesenchymal phenotype in EMT,
or UCS is not a good model for EMT.
However, this does not exclude a relevant contribution of
L1CAM expression in an early stage of EMT where cancer
cells gain motility and invasive properties. This could be by
direct function as an adhesion molecule or indirect by acting
as a signaling molecule [17, 20]. At a later stage, motility and
invasive properties may become less relevant when tumor
cells form a secondary tumor.
A strength of this study is a large cohort of 90 UCS cases
made possible through an international collaboration. The
resulting population covers well the diversity of this type of
cancer as can be seen in Table 1. Another strength is the
stepwise approach with a double stain for cases where histol-
ogy proved difficult. A limitation is the retrospective nature of
the study.
In conclusion, we describe a large cohort of 90 cases with
UCS where the majority of tumors stained positive for
L1CAM but where expression is limited to the epithelial
Table 3 Patient and tumor
characteristics and L1CAM
expression. Data exclude missing
values. FIGO = International
Federation of Gynecology and
Obstetrics
Epithelial component (n = 79)
L1CAM negative (%) L1cAM positive (%) Odds ratio (95% CI)
Age below/above 65
- 65 and below 12 (44.4) 19 (37.3) Reference 0.74
- Above 65 15 (55.6) 32 (62.7) (0.29–1.19)
FIGO stage (2009)
- I and II 18 (66.7) 28 (53.8) Reference
- III and IV 9 (33.3) 24 (46.2) 0.58 (0.22–1.54)
Myometrial invasion
- Less than 50% 14 (53.8) 26 (54.2) Reference
- More than 50% 12 (46.2) 22 (45.8) 1.01 (0.39–2.64)
Lymph node status
- Negative 14 (87.5) 21 (72.4) Reference
- Positive 2 (12.5) 8 (27.6) 0.38 (0.07–2.03)
Lymphovascular space invasion (LVSI)
- No 13 (58.1) 29 (67.4) Reference
- Yes 9 (40.9) 14 (32.6) 1.43 (0.50–4.15)
Differentiation grade carcinoma component
- Grade 2 3 (13.0) 3 (7.0) Reference
- Grade 3 18 (18.3) 39 (90.7) 2.17 (0.40–11.80)
- Undifferentiated 2 (8.7) 1 (2.3) 0.50 (0.03–8.92)
Histologic type carcinoma component
- Endometrioid 11 (52.4) 15 (35.7) Reference
- Non-endometrioid 10 (47.6) 27 (64.3) 0.5 (0.17–1.46)
Histologic type sarcoma component
- Homologue 12 (50.0) 24 (57.1) Reference
- Heterologue 12 (50.0) 18 (42.9) 1.33 (0.49–3.65)
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component. L1CAM could be involved in development of
UCS and EMT at an early stage but is not a marker for the
mesenchymal phenotype. Our study provides further insight
into the possible mechanism of EMT and metastasis.
Expression of L1CAM did not relate to unfavorable patient
and tumor characteristics, recurrence, or survival.
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